Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:RXRX

Recursion Pharmaceuticals Q3 2026 Earnings Date & Estimates

Recursion Pharmaceuticals logo
$3.95 -0.32 (-7.49%)
Closing price 10/8/2026 04:00 PM Eastern
Extended Trading
$4.01 +0.06 (+1.54%)
As of 05:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Recursion Pharmaceuticals is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Recursion Pharmaceuticals in Q3 2026

Recursion Pharmaceuticals is expected to post earnings of -$0.24 per share on revenue of $12.98 million. In the same quarter a year earlier Recursion Pharmaceuticals reported -$0.36 per share on revenue of $5.18 million. Recursion Pharmaceuticals last reported on August 5, 2026, posting -$0.25 per share and missing the -$0.24 consensus estimate. Recursion Pharmaceuticals has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.24
Expected Revenue
$12.98 million
Prior-Year EPS
-$0.36
Prior-Year Revenue
$5.18 million
Expected Revenue Growth
+150.8%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.25 (Missed by -$0.01)
Last Quarter Revenue
$7.67 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Recursion Pharmaceuticals Q3 2026 Earnings FAQ

Recursion Pharmaceuticals (NASDAQ:RXRX) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens.

Recursion Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Recursion Pharmaceuticals to post earnings of -$0.24 per share for Q3 2026.

The consensus revenue estimate for Recursion Pharmaceuticals is $12.98 million for Q3 2026.

Recursion Pharmaceuticals Earnings Headlines

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock: Insider Blake Borgeson Sells 50,000 Shares
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31103011
Stock Traders Buy High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)
October 7 at 1:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31094235
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
 |  Profits Run (Ad)
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 10% - Here's Why
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31088111
Recursion Pharmaceuticals (NASDAQ:RXRX) and Ionis Pharmaceuticals (NASDAQ:IONS) Head-To-Head Comparison
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086315
Most and least shorted mid- to mega-cap healthcare stocks at the end of September
October 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/most-and-least-shorted-mid-to-mega-cap-healthcare-stocks-at-the-end-of-september/ar-AA2dqMpb
See More Recursion Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Recursion Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Recursion Pharmaceuticals and other key companies, straight to your email.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals (NASDAQ:RXRX) is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience. Its pipeline has included internally discovered and developed drug candidates, as well as programs advanced through collaborations and strategic partnerships. The company’s approach combines laboratory experimentation with computational tools to support target discovery, compound design, preclinical testing and clinical development.

Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion operates as an international biotechnology organization through its research activities, partnerships and collaborations. In 2024, Recursion completed a combination with Exscientia plc, a United Kingdom-based company specializing in artificial intelligence-driven drug design, expanding Recursion’s capabilities in computational chemistry and medicine discovery. Recursion was co-founded by Chris Gibson, who serves as chief executive officer.

View Recursion Pharmaceuticals Profile
Earnings Tools